Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients
| Autor: | Jun Wada, Hisanori Morimoto, Kousuke Fukuoka, Takashi Kihara, Ai Sarai, Ai Yano, Kazushi Nakao, Hirofumi Makino, Shinji Fukuda |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Vitamin medicine.medical_specialty Time Factors Polymers medicine.medical_treatment Arginine medicine.disease_cause Gastroenterology Antioxidants Peritoneal dialysis chemistry.chemical_compound Coated Materials Biocompatible Renal Dialysis Internal medicine medicine Humans Vitamin E Sulfones Aged Aged 80 and over Transplantation business.industry Membranes Artificial Middle Aged Prognosis medicine.disease Malondialdehyde Lipoproteins LDL Oxidative Stress Endocrinology chemistry Nephrology Kidney Failure Chronic Female Hemodialysis Nitric Oxide Synthase Asymmetric dimethylarginine business Biomarkers Oxidative stress Follow-Up Studies Kidney disease |
| Zdroj: | Nephrology Dialysis Transplantation. 20:2775-2782 |
| ISSN: | 1460-2385 0931-0509 |
| DOI: | 10.1093/ndt/gfi121 |
| Popis: | Background. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase and an independent predictor of overall mortality and cardiovascular outcome in haemodialysis (HD) patients. In the present study, we compared the effects of a vitamin E-coated polysulfone membrane (PSE) and a non-vitamin E-coated polysulfone membrane (PS) on oxidative stress markers such as ADMA. Methods. Thirty-one HD patients were enrolled to this investigation. They were allocated into two groups: in the PSE group (n= 16), PSE was used for 6 months, followed by PS for an additional 12 months; in the PS group (n= 15), PS was used for the entire observation period. Plasma ADMA, oxidized low density lipoprotein (Ox-LDL) and malondialdehyde LDL (MDA-LDL) levels were measured at baseline, 3, 6, 12 and 18 months. Plasma ADMA in peritoneal dialysis (PD) patients and in healthy individuals was also measured. Results. Predialysis concentrations of ADMA (0.72± 0.13 nmol/ml) were significantly higher in the HD group than in both PD patients (0.63 ± 0.10 nmol/ml, P < 0.01) and healthy individuals (0.44 ± 0.01 nmol/ml, P < 0.0001). Treatment with PSE for 6 months significantly reduced predialysis levels of ADMA (0.54 ± 0.09 nmol/ml) compared with baseline (0.74 ± 0.12 nmol/ml; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|